FI57056C - Foerfarande foer framstaellning av enteralt hoegresorberbara produkter av i sig svaort resorberbara hjaertglykosider - Google Patents
Foerfarande foer framstaellning av enteralt hoegresorberbara produkter av i sig svaort resorberbara hjaertglykosider Download PDFInfo
- Publication number
- FI57056C FI57056C FI772160A FI772160A FI57056C FI 57056 C FI57056 C FI 57056C FI 772160 A FI772160 A FI 772160A FI 772160 A FI772160 A FI 772160A FI 57056 C FI57056 C FI 57056C
- Authority
- FI
- Finland
- Prior art keywords
- parts
- strophanthin
- suppository
- stirring
- mixture
- Prior art date
Links
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 45
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 37
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 22
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 claims description 16
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 229940097217 cardiac glycoside Drugs 0.000 claims description 14
- 239000002368 cardiac glycoside Substances 0.000 claims description 14
- 229960003343 ouabain Drugs 0.000 claims description 14
- 229930002534 steroid glycoside Natural products 0.000 claims description 14
- MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 claims description 13
- 150000008143 steroidal glycosides Chemical class 0.000 claims description 12
- 239000000829 suppository Substances 0.000 claims description 10
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 claims description 9
- GILGYKHFZXQALF-UHFFFAOYSA-N k-Strophantylside Natural products O1C(C)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 GILGYKHFZXQALF-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 239000004034 viscosity adjusting agent Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 description 23
- 229960002446 octanoic acid Drugs 0.000 description 18
- 239000002775 capsule Substances 0.000 description 17
- 239000013543 active substance Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940082663 other cardiac glycosides in atc Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762631214 DE2631214A1 (de) | 1976-07-12 | 1976-07-12 | Verfahren zur erhoehung der loeslichkeit von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln |
| DE2631214 | 1976-07-12 | ||
| DE2652508 | 1976-11-18 | ||
| DE19762652508 DE2652508A1 (de) | 1976-11-18 | 1976-11-18 | Oral zu verabreichende arzneimittel |
| DE2654386 | 1976-12-01 | ||
| DE19762654386 DE2654386A1 (de) | 1976-12-01 | 1976-12-01 | Verfahren zur herstellung einer fuellmasse aus mono- und diglyceriden mittelkettiger fettsaeuren zum zwecke deren verarbeitung in gelatinekapseln |
| DE19762654844 DE2654844A1 (de) | 1976-12-03 | 1976-12-03 | Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation |
| DE2654844 | 1976-12-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI772160A7 FI772160A7 (cs) | 1978-01-13 |
| FI57056B FI57056B (fi) | 1980-02-29 |
| FI57056C true FI57056C (fi) | 1980-06-10 |
Family
ID=27432127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI772160A FI57056C (fi) | 1976-07-12 | 1977-07-11 | Foerfarande foer framstaellning av enteralt hoegresorberbara produkter av i sig svaort resorberbara hjaertglykosider |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4202888A (cs) |
| JP (1) | JPS5329917A (cs) |
| DD (1) | DD131344A5 (cs) |
| DK (1) | DK313277A (cs) |
| ES (1) | ES460642A1 (cs) |
| FI (1) | FI57056C (cs) |
| FR (1) | FR2365338A1 (cs) |
| GR (1) | GR70745B (cs) |
| NO (1) | NO772444L (cs) |
| PT (1) | PT66789B (cs) |
| SE (1) | SE7708040L (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| AT358530B (de) * | 1978-04-25 | 1980-09-10 | Plc Pharma Licences | Stabilisierungsverfahren |
| FR2427100A1 (fr) * | 1978-06-02 | 1979-12-28 | Kali Chemie Pharma Gmbh | Composition pharmaceutique a propriete de resorption amelioree et procede pour sa fabrication |
| US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| SE426548B (sv) * | 1978-12-05 | 1983-01-31 | Haessle Ab | Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer |
| SE7813246L (sv) * | 1978-12-22 | 1980-06-23 | Haessle Ab | Fast farmaceutisk beredning innehallande kroppar med flera ytskikt |
| JPS56140915A (en) * | 1980-04-07 | 1981-11-04 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for solid drug |
| JPS6013720A (ja) * | 1983-07-01 | 1985-01-24 | Nitto Electric Ind Co Ltd | 生理的活性剤の吸収促進剤 |
| US4590190A (en) * | 1983-07-01 | 1986-05-20 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent |
| US4605670A (en) * | 1984-02-01 | 1986-08-12 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering metoclopramide |
| JPS60193316U (ja) * | 1984-06-04 | 1985-12-23 | 株式会社新潟鐵工所 | バケツトコンベア装置 |
| JPH0415691Y2 (cs) * | 1985-12-25 | 1992-04-08 | ||
| JP2802330B2 (ja) * | 1988-07-01 | 1998-09-24 | 株式会社資生堂 | 直腸投与組成物 |
| DE3919982A1 (de) * | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
| WO1991013601A1 (en) * | 1990-03-15 | 1991-09-19 | Rhône-Poulenc Rorer International (Holdings) Inc. | Calcitonin suppository formulations |
| TW224048B (cs) * | 1992-03-30 | 1994-05-21 | Hoechst Roussel Pharma | |
| US5470839A (en) * | 1993-04-22 | 1995-11-28 | Clintec Nutrition Company | Enteral diet and method for providing nutrition to a diabetic |
| US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
| FR2781373B1 (fr) * | 1998-07-07 | 2001-09-21 | Pf Medicament | Formulations thixotropes pour le remplissage de gelules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3458628A (en) * | 1966-02-11 | 1969-07-29 | Boehringer & Soehne Gmbh | Acovenoside derivatives |
| NL130587C (cs) * | 1966-12-22 | |||
| US3531462A (en) * | 1967-05-19 | 1970-09-29 | Shionogi Seiyaku Kk | Carbonates of cardenolide tridigitoxosides and ester derivatives thereof |
| DD113355A1 (cs) * | 1972-06-15 | 1975-06-05 | ||
| DE2233147A1 (de) * | 1972-07-06 | 1974-01-24 | Boehringer Mannheim Gmbh | Dihydrodigoxin-derivate |
| JPS4971127A (cs) * | 1972-11-18 | 1974-07-10 | ||
| DE2319874C2 (de) * | 1973-04-19 | 1983-06-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue Derivate des Digitoxigenin-α-L-arabinosids, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US3966918A (en) * | 1973-12-12 | 1976-06-29 | Nippon Shinyaku Co., Ltd. | Method of preparing aqueous solutions of sterol glycosides and their ester derivatives |
| GB1468473A (en) * | 1974-08-14 | 1977-03-30 | Nippon Shinyaku Co Ltd | Method for the preparation of steryl beta-d-glucoside palmitates |
-
1977
- 1977-07-07 US US05/813,456 patent/US4202888A/en not_active Expired - Lifetime
- 1977-07-08 FR FR7721073A patent/FR2365338A1/fr active Pending
- 1977-07-08 PT PT66789A patent/PT66789B/pt unknown
- 1977-07-08 DD DD7700199970A patent/DD131344A5/xx unknown
- 1977-07-09 GR GR53930A patent/GR70745B/el unknown
- 1977-07-11 ES ES460642A patent/ES460642A1/es not_active Expired
- 1977-07-11 SE SE7708040A patent/SE7708040L/ not_active Application Discontinuation
- 1977-07-11 FI FI772160A patent/FI57056C/fi not_active IP Right Cessation
- 1977-07-11 NO NO772444A patent/NO772444L/no unknown
- 1977-07-11 DK DK313277A patent/DK313277A/da unknown
- 1977-07-12 JP JP8335477A patent/JPS5329917A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES460642A1 (es) | 1978-07-16 |
| FI57056B (fi) | 1980-02-29 |
| PT66789B (en) | 1978-12-19 |
| JPS5329917A (en) | 1978-03-20 |
| DK313277A (da) | 1978-01-13 |
| US4202888A (en) | 1980-05-13 |
| DD131344A5 (de) | 1978-06-21 |
| GR70745B (cs) | 1983-03-14 |
| PT66789A (en) | 1977-08-01 |
| NO772444L (no) | 1978-01-13 |
| FI772160A7 (cs) | 1978-01-13 |
| SE7708040L (sv) | 1978-01-13 |
| FR2365338A1 (fr) | 1978-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI57056C (fi) | Foerfarande foer framstaellning av enteralt hoegresorberbara produkter av i sig svaort resorberbara hjaertglykosider | |
| US4066756A (en) | Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin | |
| US11766445B2 (en) | Oral soft gel capsule containing psychedelic compound | |
| DE69419019T2 (de) | Gelatinekaiseln die eine hochdosierte acetaminophenlösung enthalten | |
| CH634749A5 (de) | Arzneimittelzubereitung mit verbesserter resorptionseigenschaft und verfahren zu deren herstellung. | |
| BG97644A (bg) | Фармацевтични препарати | |
| JPS6322032A (ja) | ゼラチン封入徐放性組成物及びその製造方法 | |
| JPS62114911A (ja) | 経口投与型徐放性医薬製剤 | |
| AU2010332797B2 (en) | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | |
| JPS5988420A (ja) | シ−ムレスカプセル化ニフエジピン製剤 | |
| JPS6024767B2 (ja) | 腸溶性硬カプセル剤 | |
| JPS63406B2 (cs) | ||
| US4687766A (en) | Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases | |
| CA1099641A (en) | Pharmaceutical composition containing chromone derivatives | |
| GB1600639A (en) | Medicament preparation having resorption properties and method of producing the same | |
| DE3602577A1 (de) | 9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen | |
| CN103054799B (zh) | 一种盐酸胺碘酮注射乳剂及其制备方法 | |
| FI89004B (fi) | Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat | |
| EA001905B1 (ru) | Лекарственная форма сертралина в виде раствора, заключенного в желатиновые капсулы | |
| CA1087985A (en) | Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof | |
| US2870060A (en) | Stable encapsulated solution of a salt of a dialkyl sulfosuccinate | |
| KR810000901B1 (ko) | 카디아크 글리코사이드의 제제방법 | |
| US4405597A (en) | Medicament capsules for rectal application | |
| RU2666242C1 (ru) | Пероральная лекарственная форма 3,3'-дииндолилметана | |
| JP2938579B2 (ja) | 消化管壁保護剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: KALI-CHEMIE PHARMA GMBH |